CJC-1295 DAC (Decapeptidase-Cleaved) 5MG
CJC-1295 DAC is a modified derivative of the synthetic peptide CJC-1295, designed for research applications in the study of growth hormone (GH) signaling pathways. This compound is commonly investigated in preclinical studies to explore its role in pituitary gland function, neuroendocrinology, and metabolic processes. CJC-1295 DAC may be studied for its potential impact on hormone release, receptor binding, and downstream physiological effects.
Research Context
CJC-1295 DAC represents a truncated form of CJC-1295, which itself is a potent non-peptide agonist of the growth hormone-releasing hormone (GHRH) receptor. The decapeptidase-cleaved version (DAC) retains structural elements that allow for investigation of how truncation affects receptor binding affinity and biological activity. Research in animal models often explores the pharmacokinetic properties, tissue distribution, and functional consequences of this compound in conditions such as growth retardation, metabolic dysfunction, or neurodegenerative studies.
Research Overview
CJC-1295 DAC is primarily utilized in basic and translational research to examine:
- Growth hormone (GH) secretion and release mechanisms in response to exogenous administration.
- Potential effects on insulin-like growth factor-1 (IGF-1) levels and metabolic regulation.
- Behavioral and physiological adaptations in controlled experimental settings.
- Comparative pharmacokinetics and receptor binding efficiency versus its parent compound (CJC-1295).
Preclinical studies may also investigate its effects in models of aging, cachexia, or hormonal imbalance to assess therapeutic potential in disease models.
Key Research Focus Areas
| Research Domain | Specific Applications |
|---|---|
| Endocrinology | Investigation of pituitary hormone axis dynamics, particularly GH secretion. |
| Metabolic Studies | Assessment of IGF-1 modulation and potential implications in obesity or diabetes research. |
| Neuroendocrinology | Examination of central nervous system regulation of GH-releasing factors. |
| Pharmacokinetics | Comparative analysis of DAC versus native CJC-1295 in pharmacokinetic profiles. |
| Toxicology | Safety profiling in controlled experimental toxicity assessments. |
This peptide is intended exclusively for use in accredited research laboratories or academic institutions following protocols approved by relevant regulatory bodies. Always adhere to institutional guidelines for handling synthetic compounds in a research environment.
Important Compliance Notice
For research use only. Not for human or animal consumption. This product is not intended for therapeutic, diagnostic, or cosmetic applications. Distribute solely within approved research settings. Consult institutional biosafety protocols before use.
Reviews
There are no reviews yet.